CQP(SZ:000950)2025-10-10 10:40Financial Performance - The estimated net profit for the period from January 1, 2025, to September 30, 2025, is expected to be positive and on the rise[1] - The net profit attributable to shareholders for the current reporting period is 358 million yuan, representing a year-on-year increase of 22.51%[2] - The net profit after deducting non-recurring gains and losses is 348 million yuan, reflecting a year-on-year growth of 25.48%[2] - Basic earnings per share for the current period is 0.20 yuan, compared to 0.17 yuan in the same period last year[2] Revenue Growth - The company’s revenue growth is attributed to the continuous development of pharmaceuticals, medical devices, traditional Chinese medicine, specialty pharmacies, and emerging businesses[4] Operational Efficiency - The company has improved operational efficiency through refined management, leading to cost reduction and increased effectiveness[4] Future Outlook - The specific financial data will be disclosed in the company's Q3 2025 report, and investors are advised to pay attention to investment risks[5]